Edition:
United States

Profile: Glaukos Corp (GKOS.N)

GKOS.N on New York Stock Exchange

67.23USD
17 May 2019
Change (% chg)

$-1.61 (-2.34%)
Prev Close
$68.84
Open
$67.99
Day's High
$69.63
Day's Low
$66.96
Volume
71,705
Avg. Vol
72,600
52-wk High
$83.14
52-wk Low
$33.83

Glaukos Corporation, incorporated on July 14, 1998, is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It has developed the micro-invasive glaucoma surgery (MIGS) to serve as an alternative to the traditional glaucoma treatment and management paradigm. It offers iStent, an MIGS device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

iStent inject trabecular micro-bypass stent

The iStent Inject is designed to allow the surgeon to inject these stents into multiple trabecular meshwork locations through a single corneal entry. It is developing two versions of this product: One version of the iStent Inject is being evaluated in a pivotal United States IDE clinical trial for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. A second version of the iStent Inject is designed to make its selfsealing corneal needle penetration to achieve insertion without an incision.

iStent supra suprachoroidal micro-bypass stent

The iStent Supra is designed to reduce intraocular pressure by accessing the eye's suprachoroidal space in the eye. The iStent Supra device is approved for marketing in the European Union and certain other countries, primarily in the Middle East.

iDose

The iDose is a targeted injectable drug delivery system that is based on its micro-scale platform. The iDose implant is designed to be pre-loaded into a small-gauge needle and injected into the eye through a self-sealing corneal needle penetration, where it is secured within the eye.

The Company competes with Novartis International AG, Abbott Medical Optics Inc., Allergan plc, STAAR Surgical Company, Lumenis Ltd., Santen Pharmaceutical Co., Ltd., NeoMedix, Inc. and Ellex Medical Lasers Limited.

Company Address

Glaukos Corp

229 Avenida Fabricante
SAN CLEMENTE   CA   92672-7531
P: +1949.3679600
F: +1949.3679984

Company Web Links